Skip to NavigationSkip to content

Johnson & Johnson

Janssen closes plant in California, 49 positions axed

Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California.

The Johnson & Johnson subsidiary took over the plant in 2001, after the healthcare conglomerate acquired the Palo Alto-based ALZA Corporation for $10.5 billion.

However the permanent closure will see 49 workers lose their jobs, as Janssen announced their decision to close the Vacaville facility. The firm said that the plant was no longer needed due to a shift in focus towards other areas.

Indian authorities say J&J's baby shampoo contains 'harmful ingredients'

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful ingredients.’

The Rajasthan Drugs Control Organisation's said in a notice date 5 March, that samples of J&J’s baby shampoo had failed quality tests. The US healthcare conglomerate rejected the claims.

J&J bows to PETA pressure and drops forced swim tests in mice

Johnson & Johnson has announced it is to end its practice of forced swim tests on mice, rats and other animals in the research of new drug treatments, following discussion with animal rights advocacy group PETA. The company’s pledge means it will not use the test from now on in either its own or external laboratories.

Forced swimming tests – or behavioural despair tests, as they are also known – involve placing a mouse or rat in an acrylic cylinder from which they cannot escape as it slowly fills with water.

J&J to include prices in drug ads on TV

US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for its drugs.

The world’s largest healthcare company will become the first to take action after President Trump called on pharma firms to include prices in adverts of drugs on TV.

The healthcare conglomerate will include both the list price of the products being advertised as well as the out-of-pocket costs the consumer should expect to pay.

J&J shares plummet after asbestos cover up allegations emerge

Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based multinational had known its talcum powders had been contaminated with asbestos since the 1970s.

In reviewing documents made public by courts, Reuter’s investigators found that J&J had been aware that their baby powders were contaminated with trace amounts of asbestos since at least 1971.

NHS scraps restriction on availability of J&J's Imbruvica in leukaemia patients

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), expanding its use to cover treatment-naïve patients with chronic lymphoblastic forms of the condition (CLL).

The drug was originally approved in January last year as a treatment for CLL in patients whose cancer had returned following chemotherapy, but despite a recommendation of its efficacy from NICE, NHS England reportedly skirted clinical professionals to restrict its use to only those who had relapsed in the last t

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy of its SGLT2 inhibitor Invokana (canagliflozin), but not because it had proved ineffective.

On the contrary, after the drug met its pre-specified efficacy criteria in the prevention of clinically important renal and cardiovadcvular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), the company deemed it pertinent to close the study early.

J&J's second-in-command to retire, alongside executive restructure

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the company effective 1 October this year, triggering and executive-level shift at the firm. Following her departure, the vacated role will be shared as of 2 July by Chief Scientific Officer Paul Stoffel and Joaquin Duato, leader of J&J’s global pharmaceuticals business, where they will both hold the title of Vice Chairman.

J&J continues to shed assets, with $2.1bn diabetes unit sale

Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, potentially bringing in $2.8 billion. It has now revealed that it has accepted a $2.1 billion offer for LifeScan from Platinum Equity.

J&J actually received the first offer back in March and were given a deadline of mid-June to decide whether to accept the offer.

J&J looks to trim business with $2.8bn sale

Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive to sell its medical-sterilisation unit for $2.8 billion.

The deal consists of $2.7 billion in cash and $0.1 billion of retained net receivables.

For J&J, it is trying to divest units that have slower growth compared to the rest of the business. After its $30 billion deal for Actelion, it is clearly trying to focus on the higher growth area of pharmaceuticals into the long-term.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches